The effect of an HMG-CoA reductase inhibitor on arteriosclerotic nanoplaque formation and size in a biosensor model.
Siegel, G
The effect of an HMG-CoA reductase inhibitor on arteriosclerotic nanoplaque formation and size in a biosensor model. [electronic resource] - Biosensors & bioelectronics May 2003 - 635-47 p. digital
Publication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
0956-5663
10.1016/s0956-5663(03)00034-4 doi
Adsorption
Arteriosclerosis--blood
Biosensing Techniques--methods
Calcinosis--blood
Calcium--metabolism
Coated Materials, Biocompatible--chemical synthesis
Diabetes Mellitus, Type 2--complications
Fatty Acids, Monounsaturated--therapeutic use
Fluvastatin
Heparan Sulfate Proteoglycans--chemistry
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors--therapeutic use
Hypolipidemic Agents--therapeutic use
Indoles--therapeutic use
Lipoproteins--blood
Materials Testing
Models, Biological
Particle Size
Silicon Dioxide--metabolism
Surface Properties--drug effects
Treatment Outcome
The effect of an HMG-CoA reductase inhibitor on arteriosclerotic nanoplaque formation and size in a biosensor model. [electronic resource] - Biosensors & bioelectronics May 2003 - 635-47 p. digital
Publication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
0956-5663
10.1016/s0956-5663(03)00034-4 doi
Adsorption
Arteriosclerosis--blood
Biosensing Techniques--methods
Calcinosis--blood
Calcium--metabolism
Coated Materials, Biocompatible--chemical synthesis
Diabetes Mellitus, Type 2--complications
Fatty Acids, Monounsaturated--therapeutic use
Fluvastatin
Heparan Sulfate Proteoglycans--chemistry
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors--therapeutic use
Hypolipidemic Agents--therapeutic use
Indoles--therapeutic use
Lipoproteins--blood
Materials Testing
Models, Biological
Particle Size
Silicon Dioxide--metabolism
Surface Properties--drug effects
Treatment Outcome